CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 1 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.


Player Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:21:59 PM : Outperform Start Price: $1.35 CTIC Score: +3.29

Strong catalysts in December and January. Target price in $3 for a shor-term.

Featured Broker Partners